Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of <sup>177</sup>Lu-DOTATATE PRRT

Eva Medaer(KU Leuven), Christophe M. Deroose(KU Leuven), Olivier Gheysens(Cliniques Universitaires Saint-Luc), Sander Jentjens(KU Leuven), Karolien Goffin(KU Leuven), Kristiaan Nackaerts(Heidelberg University), Annouschka Laenen(Statistics Belgium), Jeroen Dekervel(Universitair Ziekenhuis Leuven), Koen Van Laere(Universitair Ziekenhuis Leuven), Chris Verslype(Universitair Ziekenhuis Leuven), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven)
Acta Oncologica
February 8, 2020
10.1080/0284186x.2020.1723161
Cited by 10

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k